Global Clinical Development -General Medicine
RFB002/Ranibizumab
Clinical Trial Protocol CRFB002H2301E1 / [STUDY_ID_REMOVED]
RAINBOW extension study : an extension study to ev aluate 
the long term efficacy and safety of RAnibizumab 
compared w ith laser therapy for the treatment of INfants 
BOrn prematurely With retinopathy of prematurity
Document type: Amended Protocol Version
EUDRACT number: 2014 -004048 -36 (PIP number: 000527- PIP04 -13)
Version number: v0
2 (Clean )
Clinical trial phase: III
Release date: 10-Jul-2019
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 03 ( August 2015)

[COMPANY_001] Confidential Page 2
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Table of contents
Table of contents ................................................................................................................. [ADDRESS_387554] of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 8
Amendment 2 ...................................................................................................................... 9
Protocol summary .............................................................................................................. 11
1Introduction ....................................................................................................................... 15
1.1 Back ground ............................................................................................................ 15
1.1.1 Ranibizumab ......................................................................................... 16
1.2 Purpose .................................................................................................................. 19
2Study  objectives and endpoints ......................................................................................... 19
2.1 Primary  objective(s) ............................................................................................... 19
2.2 Secondary  objective(s) ........................................................................................... 19
19
2.4 Objectives and related endpoints ........................................................................... 19
3Investigational plan ........................................................................................................... 25
3.1 Study  design ........................................................................................................... 25
3.2 Rationale for stud y design ..................................................................................... 25
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....26
3.4 Rationale for choice of comparator ....................................................................... 26
3.5
Purpose and timing of interim anal yses/design adaptations .................................. 26
3.5.1 Interim anal ysis 1.................................................................................. 26
3.5.2 Interim analysis 2.................................................................................. 27
3.6 Risks and benefits .................................................................................................. 27
4Population .......................................................................................................................... 29
4.1 Inclusion criteria .................................................................................................... 29
4.2 Exclusion criteria ................................................................................................... 30
5Treatment ................................ ................................ ................................ ........................... 30
5.1 Study  treatment ...................................................................................................... 30
5.1.1 Investigational and control drugs .......................................................... 30
5.1.2 Additional treatment .............................................................................. 30
5.2 Treatment arms ...................................................................................................... 30
5.3
Treatment assignment and randomization............................................................. 31
5.4 Treatment blinding ................................................................................................. 31

[COMPANY_001] Confidential Page 3
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
5.[ADDRESS_387555] -study  treatment .......................................... 35
5.6.2 Discontinuation of Study Treatment ..................................................... 35
5.6.3 Premature patient withdrawal from the stud y
....................................... 35
5.6.4 Loss to follow -
up .................................................................................. 36
5.6.5 Early study termination by [CONTACT_456] ................................................. 36
6
Visit schedule and assessments ......................................................................................... 36
6.1 Information to be collected on screening failures .................................................. 42
6.2 Patient demographics/other baseline characteristics ............................................. 42
6.3 Treatment exposure and compliance
..................................................................... 42
6.4 Efficacy .................................................................................................................. 42
6.4.1 Ophthalmic fundus features .................................................................. 42
6.4.2 Ocular and visual function .................................................................... 43
6.4.3 Visual Acuity
 (VA) ............................................................................... 43
6.4.4 Appropriateness of efficacy  assessments .............................................. 44
6.5 Safety ..................................................................................................................... 44
6.5.1 Ocular examination ............................................................................... 44
6.5.2 Vital signs .............................................................................................. 44
6.5.3 Health status .......................................................................................... 45
6.5.4 Laboratory  evaluations .......................................................................... 45
6.5.5 Appropriateness of safety  measurements .............................................. 45
46
46
7Safety  monitoring .............................................................................................................. 46
7.1 Adverse events ................................ ................................ ................................ .......46
7.2 Serious adverse events ........................................................................................... 48

[COMPANY_001] Confidential Page 4
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
7.2.1 Definition of SAE ................................................................................. 48
7.2.2 SAE reporting
........................................................................................ 49
7.3 Reporting of stud y treatment errors ....................................................................... 50
8Data review and database management ............................................................................. 51
8.1 Site monitoring ...................................................................................................... 51
8.2
Data collection....................................................................................................... 51
8.3 Database management and quality  control ............................................................ 51
8.4 Data Monitoring Committee .................................................................................. 52
8.5 Adjudication Committee ........................................................................................ 52
9Data analy sis...................................................................................................................... 52
9.1 Analy sis sets .......................................................................................................... 53
9.2
Patient demographics and other baseline characteristics....................................... 53
9.3 Treatments (stud
y drug, rescue medication, other concomitant therapi [INVESTIGATOR_014], 
compliance) ............................................................................................................ 53
9.4 Analy sis of the primary  variable(s) ....................................................................... 54
9.4.1 Variable(s) ............................................................................................. 54
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 54
9.4.3 Handling of missing values/censoring/discontinuations ....................... 55
9.4.4 Sensitivity  analy ses............................................................................... 55
9.5 Analy sis of secondary  variables
............................................................................ 55
9.5.1 Efficacy  variables
.................................................................................. 55
9.5.2 Safety
 variables ..................................................................................... 56
57
9.7 Interim anal yses..................................................................................................... 57
9.8
Sample size calculation.......................................................................................... 59
10Ethical considerations ................................ ................................ ................................ ........ 59
10.1 Regulatory and ethical compliance ........................................................................ 59
10.2 Informed consent procedures
................................................................................. 59
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. [ADDRESS_387556] of tables
Table 2
-1 Objectives and related endpoints .......................................................... 20

[COMPANY_001] Confidential Page 5
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Table 5-1 Study  ranibizumab dose in Extension study  based on treatment 
received at the baseline visit in core study  (CRFB002H2301) ............. 33
Table 5-2
Treatment which prohibits further use of study  ranibizumab ............... 34
Table 6-1 Main Assessment Schedule ................................................................... 38
Table 6
-2 Additional Assessment Schedule –Treatment with Ranibizumab .......[ADDRESS_387557] of figures
Figure 1 -1 Predicted Sy stemic Exposure After Anti -VEGF Treatment, 
Classified Based on Toxicological Outcomes ....................................... 18
Figure 3 -
1 Study  design .......................................................................................... 25

[COMPANY_001] Confidential Page 6
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
List of abbreviations
AE Adverse Event
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ANOVA Analysis of variance
AST Aspartate Aminotransferase
ATC Anatomical Therapeutic Chemical (classification s ystem)
BEAT -ROP Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity 
(study)
BUN Blood urea nitrogen
CFR US Code of Federal Regulations 
CPO Countr y Pharma Organization
CRF Case Report/Record Form (paper or electronic)
CTT Clinical Trial Team
DMC Data Monitoring Committee
DS&E Drug Safety & Epi[INVESTIGATOR_314868]/Record Form
EMA
EEA
ETDRSEuropean Medicines Agency
European Economic Area
Early Treatment Diabetic Retinopathy Study
ETROP Early Treatment for Retinopathy of Prematurity (study)
EU
GCP
GDPREuropean Union
Good Clinical Practice
General Data Protection Regulation
Hb Hemoglobin
IB Investigator’s Brochure
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
Ig Immunoglobulin
IRB Institutional Review Board
IRT Interactive Response Technology
MedDRA Medical dictionary for regulatory activities 
OC/RDC Oracle Clinical/Remote Data Capture
PIP EU Pediatric Investigation Plan
PLT Platelet count
ROP Retinopathy of Prematurity
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SmPC Summary  of Product Characteristics
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
VA Visual Acuity 

[COMPANY_001] Confidential Page 7
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
VEGF Vascular endothelial growth factor
WCC White Cell Count
WHO World Health Organization 
WoC Withdrawal of Consent

[COMPANY_001] Confidential Page 8
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_314892] A child’s chronological ageisits age referring to the date ofbirth
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Corrected age A child’s c orrected ageisits chronological age corrected for its 
prematurity, i.e. c alculated by [CONTACT_314893] t hechronological age
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 
mg once a day, 75 mg twic e a day)
Enrollment Point/time of patient entry into the study at which informed consent 
must be obtained (e.g. prior to starting any of the procedures 
described in the protocol)
Epoch A portion of the study which serves a specific purpose. T ypi[INVESTIGATOR_18501]: screening/recruitment, wash -out, treatment, and follow -up
Investigational drug The drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is s ynon ymous with 
“investigational new drug” or “investigational medicinal product.”
Medication pack number A unique identifier on the label of each investigational drug package
Patient/subject ID A unique number assigned to each patient upon signing the informed 
consent
Personal Data Subject information collected by [CONTACT_5336]. This data includes subject 
identifier information, study information and biological samples.
Randomization number A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Study drug/ treatment Any single drug or combination of drugs administered to the patient as 
part of the required study procedures; includes investigational drug (s), 
placeb o/comparator active drug run -ins or background therapy
Study Treatment 
DiscontinuationWhen the investigator permanently stops to administer study treatment 
to the patient prior to the defined study  treatment completion date
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in the study
Withdrawal of study 
consent (W oC)Withdrawal of consent from the study occurs only when a patient ’s 
parent(s) or legal gu ardian(s) does not want the patient to participate 
in the study any longer and does not allow any further collection of 
personal data.

[COMPANY_001] Confidential Page 9
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Amendment 2
Amendment rationale
The main purpose of this amendment is to:
Include the requirement for masked VA assessments to be performed at the child’s 5th
birthday  visit following a Health Authority  request .
Changes to the protocol
Major changes are made to the protocol in the following sections:
Protocol summary andSection 3.1 “Study  Design” : The section s wereamended to update 
language that the VA assessor conducting the child’s 5thyear birthday  visit will be masked 
to treatment.
Section 5.4 “Treatment Blinding”: The section was amended to update the study  design 
open label language and clarify  that the VA assessor conducting the child’s 5thyear 
birthday  visit will be masked to t reatment.
Section 6.4.3 “Visual Acuity  (VA) ”: The section was amended to require a masked 
assessor to perform VA assessments at the child’s 5thbirthday  visit.
Changes to specific sections of the protocol areshown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/ IECs
A copy  of this amended protocol will be sent to the Institutional Review Board (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities. 
The changes described in this amended protocol require IRB/ IEC and Health Authority 
approval according to local regulations prior to implementation.
The changes herein do NOT affect the trial specific global model consent form .
Summary  of previous amendments
Amendment 1 (31-Jul-2018)
Amendment rationale
The main purpose of this amendment is to:
Collect additional visual function data following EU national scientific advice meeting.
In addition, further purpose of this amendment is to:
Updat ethe primary  hypothesis testing to also include a scenario where the primary  
efficacy  variable of the core study (CRFB002H2301) does not meet the pre- defined 
statistical significance level: In this case , the primary  objective will onl y be anal yzed 
using descriptive statistics.
Changes to the protocol
Major changes are made to the protocol in the following sections:

[COMPANY_001] Confidential Page 10
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Section 6 “Visi t schedule and assessments” : A supplemental visit and additional vision 
tests at the child’s 2 and 3 y ears’ corrected age visits were added to assess visual function .
“Protocol summary ”, Section 9.4 “Analy sis of the primary  variable(s) ”and Section 9.5
“Anal ysis of secondary  variables” : Wordin g updated to reflect the change in the anal ysis 
of the primary  objective
Other changes are made to the protocol in the following section s:
Section [IP_ADDRESS] “Withdrawal of informed consent ”was updated to reflect the new requirements 
of the General Data Protection Regulation (GDPR) within the European Economic Area (EEA).
Section 
6.4.3 “Visual Acuity ”was updated, details of VA assessment wereremoved for clarit y.
In addition, this amendment incorporates editorial changes to the protocol language to enha nce 
consistency  and clarity  throughout the protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/ IECs
A copy  of this amended protocol will be sent to the Institutional Review Board (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities. 
The changes described in this amended protocol require IRB/ IEC and Health Authority 
approval prior to implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 11
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Protocol summary
Protocol number CRFB002H2301 E1
Title RAINBOW  extension study: an extension study to evaluate the long term 
efficacy  and safety of RAnibizumab compared with laser therapy for the
treatment of INfants BOrn prematurely With retinopathy of prematurity
Brief title RAINBOW  extension study
Sponsor and Clinical 
Phase[COMPANY_001] ; Phase 3
Investigation type Drug
Study type Interventional
Purpose and rationale The purpose of this study  is to evaluate the long term efficacy  and safety 
of intravitreal ranibizumab compared with laser ablation therapy in patients 
who were treated for retinopathy of prematurity (ROP )in the core study 
CRFB002H2301
Primary Objective( s) To evaluate the visual function of patients, by [CONTACT_314894] y 
in the better -seeing eye at the patient’s fifth birthday
Secondary Objectives To evaluate the safety outcomes by  [CONTACT_314895], frequency 
and severity of ocular and non-ocular Adverse Events (AEs)
To evaluate the visual function by [CONTACT_314896] -seeing eye at the patient’s fifth birthday
To evaluate the absence of active ROP at [ADDRESS_387558] baseline visit in the core study
To evaluate the absence of ocular structural abnormalities at [ADDRESS_387559] baseline visit in the core study, at the patient’s 2 years 
corrected age and fifth birthday
To evaluate the recurrence of ROP up to [ADDRESS_387560] baseline visit in the core study
To assess the number of ranibizumab injections received in the 
treatment of patients with ROP up to [ADDRESS_387561] baseline visit in 
the core study
To evaluate the refraction in each eye at the patient’s 2 years’ 
corrected age and fifth birthday
To evaluate the physical development at the patient’s 2 years’ 
corrected age and fifth birthday
To evaluate the health status at the patient’s 2 years’ corrected age 
and fifth birthday (respi[INVESTIGATOR_4806], hearing function, duration of 
hospi[INVESTIGATOR_059], and weight at discharge from hospi[INVESTIGATOR_307])
Study design This is a multicenter open -label extension study where theVA assessment 
at the child's 5thbirthday visit will beperformed by [CONTACT_314897]. Patients who have successfully completed the 
24-week core study CRFB002H2301 are eligible for entry into the study.
Treatm ent with study  ranibizumab will be permitted for eligible eyes up to 
and including week 40 from the baseline visit in the core study 
(CRFB002H2301) [Epoch 1]. The remainder of the extension study [Epoch 
2] is observational.
PopulationThe study population will consist of male and female preterm 
infants/children who have successfully completed the CRFB002H2301 

[COMPANY_001] Confidential Page 12
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
core study . These patients received intravitreal ranibizumab and/or laser 
therapy for retinopathy of prematurity in the core study.
Key Inclusion criteriaPatients have to fulfill all of the following criteria at baseline of the extension 
study prior to receiving the first study related pro cedure:
1.Signed informed consent from parent(s) or legal guardian(s), in 
compliance with local requirements
2.The patient successfully completed the core study CRFB002H2301, 
as defined by [CONTACT_314898] [ADDRESS_387562]
3.The patient received study treatment in both eyes at baseline of 
study CRFB002H2301
Key Exclusion criteriaPatients fulfilling any of the following criteria at study entry are not eligi ble 
for inclusion in this study:
1.Patient has a medical condition or personal circumstance which 
precludes study participation or compliance with study procedures, as 
assessed by [CONTACT_737]
2.Patient has been discontinued from the core study CRFB002H2301 
at any time
Study treatment Ranibizumab 10 mg/mL solution for injection (labeled as 
“RFB002 0.5mg/0.05 mL”) supplied in glass vials for single use by 
[CONTACT_286878]. The storage conditions will be 
described on the medication label.
Efficacy assessmentsOphthalmic fundus features
These will be assessed in both eyes by [CONTACT_314899]:
Features of active ROP disease:
ROP disease –zone, stage, extent by [CONTACT_314900], and 
characteristics of vascular changes of plus disease (extent by 
[CONTACT_314901])
Extra -retinal vessels judged to be active
Features of late sequelae of ROP / ocular structural abnormalities :
Retrolental membrane obscuring the view of the posterior pole
Substantial temporal retinal vessel dragging causing abnormal 
structural features
Posterior retinal fold involving the macula
Retinal detachment involving the macula
Retinal detachment not involving the macula
Pre-retinal fibrosis
Optic disc pallor
Optic disc swelling
Pi[INVESTIGATOR_314869] y disturbance in the macula
Atrophic changes in macula
Ocular and visual function : refraction
Visual acuity (VA)
Assessment of VA in each eye

[COMPANY_001] Confidential Page 13
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Key safety 
assessmentsOcular examination
Standing/sitting height ,weight, head circumference
Adverse event monitoring (ocular and s ystemic) ; number of 
hospi[INVESTIGATOR_059]/ prolongation due to Serious Adverse Event (SAE)
Health status (respi[INVESTIGATOR_4806], hearing function, duration of 
hospi[INVESTIGATOR_314870] f irst discharge home )
Data analysisThree planned analy ses will be conducted in the study. 
Interim analysis 1 will provide descriptive statistics for a subset of 
patients to evaluate ocular structural abnormalities. This is to comply 
with the plan for specific follow -up in the Pediatric Investigation Plan. 
Interim analysis 2 will be conducted on all patients at their 2 years’ 
corrected age to report on the progress of the study to the scientific 
community .
The final analysis will be conducted at the completion of the study.
Additional interim analy ses may be conducted on safety or efficacy  data 
as required.
All analy ses will be carried out on the Extension Safety Set and displayed 
by [CONTACT_314902]002H2301 
unless otherwise specified. One-sided p-values and two sided 95% 
confidence intervals will be displayed without adjusting for multiplicity .
If the primary hypothesis testing of the core study shows statistical 
significance, the primary  objective of the extension study will be assessed 
by [CONTACT_314903] 0.2 mg to laser of the visual 
acuit y forthe bett er-seeing eye at the patient’s fifth birthday. An analysis 
of variance ,with treatment group as a factor ,stratified by [CONTACT_314904]-
Mantel -Haenszel test.A two-way analysis of variance with treatment group 
and zone as factors will be used to estimate least squares means and 95% 
confidence intervals for visual acuit y in the better -seeing eye within and 
between treatment groups. If statistical significance in the core study 
cannot be shown , only descriptive statistics will be provided for the 
comparison between ranibizumab 0.[ADDRESS_387563] for 
proportions stratified by [CONTACT_314905].

[COMPANY_001] Confidential Page 14
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Descriptive statistics will be used to summarize other variables. All data 
will be listed.
Key wordsOpen -label, long-term, extension study ; intravitreal ranibizumab; laser 
ablation therapy; retinopathy of prematurity; preterm infants; RAINBOW

[COMPANY_001] Confidential Page 15
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
1 Introduction
1.1 Background
Retinopathy  of prematurity  (ROP) is a vasoproliferative pathologic process that occurs in the 
incompletely  vascularized, developi[INVESTIGATOR_314871]- weight preterm neonates. The 
vascular changes of ROP may be mild and regress completely  with time without major long 
term sequelae, or may increase in severity  and lead to macular dragging, total retinal detachment, 
severe visual im pairment and lifelong blindness ( Hard y et al. 2004 ). ROP is a significant cause 
of blindness in children in both developed and developi[INVESTIGATOR_314872]  50,000 
children blind from ROP worldwide ( Gilbert 2008 ,Mintz -Hittner et al. 2011 ).
In the 1990s, the use of laser photocoagulation to ablate the peripheral avascular retina gained 
widespread acceptance as standard of care treatment for ROP (Connolly  et al 2002, Ng et al. 
2002, Houston et al. 2013 ,Good 2004 ). However, despi[INVESTIGATOR_314873], ROP remains a leading cause of childhood blindness worldwide.
Laser therapy  ablates the avascular peripheral retina and destroy s the majority  of the retinal 
cells that produce vascular endothelial growth factor (VEGF), which is postulated to play an 
important role in the initiation and progression of ROP (Smith 2008). Because of the role of 
VEGF in ROP, there is a growing body  of evidence supporting the use of targeted 
pharmacologic inhibition of VEGF in the management of ROP ( Sonmez et al. 2008 ,Sato et al. 
2009).
Results from a prospective, multicenter, randomized clinical study  (BEAT -ROP study ) (Mintz -
Hittner et al. 2011) suggest that intravitreal bevacizumab may be more efficacious than 
conventional laser ablation therap y among infants with stage 3+ ROP. The prim ary outcome of 
the study  was the recurrence of retinal neovascularization before 54 weeks postmenstrual age 
that required re -treatment. I t was found that among the subgroup of infants with zone I  disease 
the recurrence rate was 6% with bevacizumab and 42% with conventional laser therap y. 
Moreover, bevacizumab therap y resulted in a mild anatomical retinal abnormality  in only [ADDRESS_387564] 
associated vascular growth. If anti-VEGF agents allow more normal retinal vascularization to 
occur, it is anticipated that the rate of abnormal visual acuity, restricted visual fields, refractive 
errors, ambl yopia, and strabismus may  be reduced. This was demonstrated when patients from 
the BEAT -ROP study  were assessed at a mean age of 2.5 years, with more myopia found in 
eyes that received laser treatment than in eyes that received intravitreal bevacizumab (Geloneck 
et al 2014 ).
Anumber of limitations have 
been noted in the BEAT -ROP study  (Darlow et al. 2013). 
Therefore, despi[INVESTIGATOR_314874]-VEGF in the treatment of ROP, a number 
of questions remain unanswered and require further study  to better understand the clinical 
efficacy  of anti-VEGF agents compared to standard of care laser therapy, the optimal dose to 

[COMPANY_001] Confidential Page 16
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
be used, as well as more information on the long -term safet y of intravitreal anti- VEGF use in a 
developi[INVESTIGATOR_314875] (Lee et al. 2011, Darlow et al. 2013). It is also important to collect more 
evidence on the longer term efficacy  and safet y outcomes in this patient group.
The study  CRFB002H2301 is a randomized, open -label, three -arm parallel- group study  to 
determine if intravitreal ranibizumab is superi or to laser ablation therap y in the treatment of 
ROP. In addition, two doses of ranibizumab are investigated (0.1 mg and 0.2mg). The study  
will assess the ability  of these treatments to lead to regression of active ROP and prevention of 
the development ofocular complications that are associated with poor visual outcome [ADDRESS_387565] study treatment (intravitreal ranibizumab or laser ablation therapy ).
This study , CRFB002H2301E1 , is an extension study  to evaluate the long term efficacy  and 
safet y of intravitreal ranibizumab compared with laser ablation therapy  in ROP patients who 
successfully completed the core stud y (CRFB002H2301).
1.1.1 Ranibizumab
Ranibizumab is a recombinant humanized immunoglobulin (Ig) G1 kappa isoty pe monoclonal 
antibody  fragmen t targeted against human VEGF -A.
Physical, Chemical, and Pharmaceutical Properties and Formulation
Detailed information on the physical, chemical and pharmaceutical properties of ranibizumab 
is described in the investigator’s brochure (IB).
Ranibizumab is available as a 10 mg/mL  solution for intravitreal injection. [COMPANY_001] is the 
marketing authorization holder for Lucentis® 10 mg/mL solution for injection in the European 
Union (EMEA/H/C/000715) and worldwide with the exception of the [LOCATION_002] of Ameri ca 
(US). The 10 mg/mL  solution for injection is approved and commercialized globall y.
The formulation is presented as a single -use sterile, clear to slightly  opalescent, colorless to pale 
yellow and preservative free aqueous solution for intravitreal injec tion supplied in glass vials. 
All primary  packaging materials are standard quality , suitable for packaging sterile liquid 
products, and compl y with relevant pharmacopoeial requirements.
A syringe suitable to accuratel y deliver volumes of [ADDRESS_387566] injection needle (e.g., 
30 G, ½ inch stainless steel) as for the adults will be used for the injection in premature neonates.
Neonatal Nonclinical and Clinical Information
The IB contains information on nonclinical studies of ranibizumab, as well as clinical studies 
in age-related macular degeneration, diabetic macular edema, retinal vein occlusion and 
pathologic myopia. Additional information relevant to the neonatal use of ranibizumab is 
described below.
Vascular endothelial growth factor plays an important angiogenic role in the embry o/fetus, 
during the postnatal period and in the adult life.

[COMPANY_001] Confidential Page 19
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
reported to increase sy stemic drug exposures b y damaging the natural barrier that represents a 
full-thickness retina (Wu et al 2011). However, no systemic complication (cardiovascular, 
respi[INVESTIGATOR_696] , neurologic or renal) attributable to bevacizumab treatment (0.4 0
-1.25 mg/ey e) has 
been recorded so far in premature neonates (Micieli et al 2009, Law et al 2010 , Sahin et al 2013,
Wu et al 2013
).
1.[ADDRESS_387567] study  interim analy sis will be conducted to comply  with the plan fo
r specific follow -
up as agree d with the Pediatric Committee at the European Medicines Agency  in the Pediatric 
Investigation Plan (see Section 3.2 ).
2 Study  objectives and endpoints
All objectives will be assessed by [CONTACT_314906]002H2301 unless otherwise specified . 
2.1 Primary  objective(s)
To evaluate the visual function of patients by [CONTACT_314894] y in the better -seeing eye 
at the patient’s fifth birthday (seeTable 2 -1).
2.2 Secondary  objective(s)
SeeTable 2-1.
2.4 Objectives and related endpoints

[COMPANY_001] Confidential Page 20
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Table 2-1 Objectives and related endpoints
OBJECTIVE Endpoint Title, Description and Reporting Time Frame for analysis and Unit 
of MeasureStat A nalysis Section
Primary
To evaluate the visual function of 
patients, by [CONTACT_314907] y in the better -seeing eye at the 
patient’s fifth birthdaya,eTitle: visual acuity in the better -seeing eye at the patient’s fifth birthday
Unit of Measure: visual acuity score (Lea s ymbols optotypes )
Description: see Section 6.4.3
Time Frame: at the patient’s fifth birthdayeSeeSection 9.4
Secondary
To evaluate the safety outcomes by  
[CONTACT_314895], frequency  and 
severit y of ocular and non -ocular 
Adverse EventsbTitle: ocular and non -ocular Adverse Events
Unit of Measure: number and percentage of patients having e.g. any AE; number of 
hospi[INVESTIGATOR_059]/ prolongation of hospi[INVESTIGATOR_314876]: see Section 7
Time Frame: from the 1st study treatment in the core study up to [ADDRESS_387568] 
baseline visit in the core study, the patient’s 2 years ’corrected age and the 
patient’s fifth birthdaySeeSection 9.5.2
To evaluate the visual function by 
[CONTACT_314896] -seeing eye at the patient’s 
fifth birthdayaTitle: visual acuity in the worse -seeing eye at the patient’s fifth birthday
Unit of Measure: visual acuity score (Lea s ymbols optotype s)
Description: see Section 6.4.3
Time Frame: at the patient’s fifth birthdaySeeSection 9.5.[ADDRESS_387569] baseline visit in the core studyTitle: absence of active ROP
Unit of Measure: number and percentage of patients
Description: see Section 3.5.1
Timeframe: at [ADDRESS_387570] baseline visit in the 
core study, at the patient’s 2 years 
corrected age and fifth birthdayTitle: absence of allocular structural abnormalities
Unit of Measure: number and percentage of patients
Description: the absence of all ocular structural abnormalities listed in Section 3.5.1
in both eyesSeeSection 9.5.1

[COMPANY_001] Confidential Page 21
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
OBJECTIVE Endpoint Title, Description and Reporting Time Frame for analysis and Unit 
of MeasureStat A nalysis Section
Time Frame: at or before [ADDRESS_387571] baseline visit in the core study, at or 
before the patient’s 2 years corrected age, at or before the patient’s fifth birthday
Title: absen ce of each ocular structural abnorma lity as listed in Section 3.5.2
considered individually
Unit of Measure: number and percentage of patients 
Time Frame: at or before week 40, at or before the patient’ s 2 y ears’corrected age, 
at or before the patient’s fifth birthday
To evaluate the recurrence of ROP 
up to [ADDRESS_387572] 
baseline visit in the core studyTitle: recurrence of ROP
Unit of Measure: number and percentage of patients with recurrence of ROP
Description: Recurrence of ROP is defined as ROP receiving any intervention after 
the 1st study  treatment in the core studyd.
Time Frame: up to [ADDRESS_387573] 
baseline visit in the core studyTitle: number of ranibizumab injections
Unit of Measure: number of ranibizumab injections
Description: as per title
Time Frame: up to and including [ADDRESS_387574] baseline visit in the core studySeeSection 9.5.2
To evaluate the refraction in each 
eye at the patient’s 2 years’ 
corrected age and fifth birthdayaTitle: refraction in each eye
Unit of Measure: diopters
Description: s ee Section 6.4.2
Time Frame: at the patient’s 2 years corrected age, patient’s fifth birthdaySeeSection 9.5.1
To evaluate the physical 
development at the patient’s 2 
years’ corrected age and fifth 
birthdaybTitle: standing/sitt ing height, leg length, weight
Unit of Measure: centimeter, gram (as appropriate)
Description: see Section [IP_ADDRESS] ; leg length will be derived from standing/sitting 
height d ifference
Time Frame: at the patient’s 2 years corrected age, at the patient’s fifth birthday
Title: head circumferenceSeeSection 9.5.2

[COMPANY_001] Confidential Page 24
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
OBJECTIVE Endpoint Title, Description and Reporting Time Frame for analysis and Unit 
of MeasureStat A nalysis Section
a-Variable corresponding to “ocular effects” in the plan for specific follow -up in the Pediatric Investigation Plan (EMA)
b- Variable corresponding to “clinical outcomes” in the plan for specific follow -up in the Pediatric Investigation Plan (EMA)
c- Variable corresponding to “neurodevelopmental outcomes” in the plan for specific follow -up in the Pediatric Investigation Plan (EMA)
d- Supplementary laser treatments (as per CRFB002H2301 study protocol) are considered part o f the complete laser treatment
e- At the visit as close as possible to the child’s fifth birthday (see Table 6 -1)

[COMPANY_001] Confidential Page 25
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
3 Investigational plan
3.1 Stud y design
This is a multicenter open -label extension study  (Figure 3-1 )where the VAassessment at the 
child's 5thbirthday  visit will beperformed by [CONTACT_314908].
Patients who have successfully  completed the 24-week core study  CRFB002H2301 are eligible 
for entry  into the study  (see Section 4). Visit 201/ baseline visit of the extension study  can occur 
on the same day  as the la st visit in the CRFB002H2301 study .
Treatment with study  ranibizumab (either as re-treatment after ranibizumab has alread y been 
injected in the same ey
e or as switch ranibizumab treatment from study  laser therapy 
administered in the core study )will be per mitted for eligible ey es up to and including the visit 
week 40 from the baseline visit in the core study  (RFB002H2301) (equal to week 16 from the 
baseline visit in extension study , when the baseline visit in extension study coincides with the 
week 24 visit in the core study ) [Epoch 1]. The remainder of the extension study  [Epoch 2] is 
observational.
Assessment visits will be performed regularl y throughout the Epoch [ADDRESS_387575] study  
visit as close as possible to the patient’s fifth birthday . The assessments related to the primary 
objective will be performed at the patient’s fifth birthday . Two interim analy ses are planned, 
seeSection 3.5.Additional interim analyses may be conducted on safety  or efficacy  data as 
required .
Figure 3-[ADDRESS_387576] 

[COMPANY_001] Confidential Page 26
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
assessment of the visual function of the patients as well as of their physical growth and cognitive 
status. Late recurrence of ROP is not expected beyond [ADDRESS_387577] study treatment 
(in the core study  CRFB002H2301), therefore the treatment period ends with the end ofthe 
Epoch 1. Interim analyseswill be performed using a snapshot of the database available at the 
cut-off points . The first interim anal ysis will be conducted t o compl y with the plan for specific 
follow -up in the Pediatric Investigation Plan (EMA) and to support the inclusion of information 
related tothetreatment of ROP in the Lucentis product information (in EU: Summary  of 
Product Characteristics (SmPC) ). The second interim analysis will be conducted to evaluate 
efficacy  and safet y data and report on the progress of the study  to the scientific community 
during the course of the study .Additional interim analyses may be conducted on safet y or 
efficacy data as required.
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
Treatment with study  ranibizumab is permitted in the Epoch [ADDRESS_387578] 
recurrence / worsening of ROP disease, in the opi[INVESTIGATOR_871].
The duration of the Epoch 1 (when treatment with study  ranibizumab is permitted) is up to and 
including [ADDRESS_387579] of care treatment for ROP in 
many  countries (Royal College of Paediatrics and Child Health 2008 , Hartnett and Penn 2012 ).
3.5 Purpose and ti ming of interim analy ses/design adaptations
3.5.[ADDRESS_387580] study treatment (in the core 
study  CRFB002H2301), whichever is the latest.
The purpose of the first interim analysis is to provide some longer term data on ocular structural 
abnormalities . This isto comply  with the plan for specific follow -up in the Pediatric 
Investigation Plan (EMA) . Therefore, the absence of ocular structural abnormalities will be 
evaluated as defined by[CONTACT_314909] [ADDRESS_387581] study treatment in the core stud y CRFB002H2301:
Substantial temporal retinal vessel dragging causing abnormal structural features/ macular 
ectopia
Retrolental membrane obscuring the view of the posterior pole
Posterior retinal fold involving the macula
Retinal detachment involving the macula

[COMPANY_001] Confidential Page 27
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Additional objectives of the interim anal ysis 1 are :
to explore the abs ence of active ROP in both eyesas defined b y the absence of allof the 
following features:
Vessel dilatation of plus d isease in at least 2 quadrants (some persisting tortuosity  is 
allowed)
Extra -retinal vessels extending from the retina into the vitreous and judged to be a 
sign of active ROP disease
to explore the recurrence of ROP
to explor e the number of ranibizumab inj ections
to explor e the safet y outcomes by [CONTACT_314910] t ype, frequency and severity of ocular and 
non-ocular Adverse Events
3.5.[ADDRESS_387582] patient has completed the visit which 
corresponds to the patient’s 2 y ears’ corrected age .
The rationale for the second interim analy sis is given in 
Section 3.2.
The purpose of the second interim analy sis is to evaluate the absence of all ocular structural 
abnormalities as defined in Section 3.5.1 at the patient’s 2 y ears’ corrected age.
Other objective s
of the second interim anal ysis are :
to evaluate the absence of each ocular structural abnormality  considered individually ,i.e.
Each ocular structural abnormality  as listed above in Section 3.5.1
Retinal detachment not involving the macula
Pre-retinal fibrosis
Optic disc pallor
Optic disc swelling
Pi[INVESTIGATOR_314877]
Atrophic changes in the macula
to evaluate the safet y outcomes by [CONTACT_314911], frequency  and severity  of ocula r 
and non
-ocular Adverse Events
Further objectives are to evaluate clinical and cognitive outcomes as per Table 2 -1.
Additional details for the interim analy ses are provided in Section 3.2 and the statistical 
considerations in Section 9.7.
3.6 Risks and benefits 
The risk to 
subjects in this trial will be minimized by [CONTACT_105234].
This study  will be an exten sion of the core study  CRF002H2301 conducted in preterm infants 
who received intravitreal ranibizumab injection and/orlaser therap yfor retinopathy  of 

[COMPANY_001] Confidential Page 28
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
prematurit y. For eligible patients, the patient ’sparent(s) or legal guardian(s) will be invited to 
allow the patient to continue in the extension study. This is a vulnerable patient population due 
to their age and associated comorbidities. To protect their rights, safety , and well-being, only 
study  centers and investigators experienced in managing these patients will be invited to 
participate in the core and extension studies.
Study  ranibizumab can be administered during the Epoch 1of the extension study  to patients 
who, in the opi[INVESTIGATOR_871] ,have a recurrence / worsening of ROP disease. This is 
toensure study  treatment is still available for potential late ROP recurrences following anti-
VEGF treatment (Chen 2014, Hu et al 2012 ). Patients not eligible for study ranibizumab 
treatment will receive the Standard of Care therapy as per local clinical practice. Based on 
published literature, late recurrences of ROP following anti-VEGF therapy  are not expected 
beyond week [ADDRESS_387583]-baseline treatment. The remainder of the extension study (Epoch 2)is 
therefore observational.
Treatment with i nvestigational ranibizumab is associated with potential risks and benefits.
The potential benefits of intravitreal anti -VEGF in the management of ROP have been 
previously  described (Section 1.1). Notably , a prospective randomized clinical study  
demonstrated that intravitreal bevacizumab, compared to laser t
herap y(the current Standard of 
Care therap y in most countries) , was more efficacious in the treatment of ROP to reduce the 
number of recurrences and was associated with less my opia in the long term ( Mintz -Hittner et 
al 2011, Geloneck et al 2014 ). Based on published information, more than [ADDRESS_387584] received ranibizumab or other anti-VEGF intravitreal injections. Ranibizumab treatment 
has the potential advantage versus laser therapy  of being able to treat ROP without causing 
widespread damage to the peripheral retina, thereby [CONTACT_314912] e, preserving the visual field s
.
In adults, ranibizumab has been shown to improve vision and help prevent visual loss in adults 
with age related macular degenerati on, visual impairment due to pathologic myopia or diabetic 
macular edema or retinal vein occlusion.
Potential risks with the use of intravitreal anti-VEGF agents, as identified in published case 
reports, include the development of late retinal detachment and reduction in systemic VEGF 
levels (Honda et al 2008, Jang et al 2010, Lee et al 2010, Zepeda -Romero et al 2010, Hu et al 
2012, Sato et al 2012, Hoerster et al 2013). Furthermore, risks associated with the intravitreal 
injection procedure include endophthalmitis, retinal detachment, traumatic cataract, and 
increased intraocular pressure.
Serum VEGF levels in ROP infants following ranibizumab have been measured in two studies 
(Hoerster et al. 2013
,Zhou et al. 2015 ). Hoerster et al. 2013 describe done infant whose VEGF 
levels were reduced 1 week after ranibizumab injection, were further reduced below detection 
limit at week 3 and returned to normal levels at week 4. Zhou et al. 2015 measured plasma 
VEGF levels before and 1 day after ranibizumab injection in 5 ROP infants: plasma VEGF 
levels were reduced to between 9% and 37% of pre -dose VEGF levels 1 day after the injection 
and normalized after 1 week.
Potential risks of systemic inhibition of VEGF may include disturbances of organ and 
neurologi cal development, renal impairment, bone abnormalities, and thromboembolic events. 

[COMPANY_001] Confidential Page 29
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
These effects were observed in studies using animal knockout models, in nonclinical and 
clinical studies with high systemic doses of anti-VEGF agents or in clinical studies of 
intravitreal 
anti-VEGF in adults with predisposing comorbidities. No such systemic adverse 
effects have been reported in the publish ed reports of intravitreal anti -VEGF therapy  in ROP. 
Nonetheless, all patients will be monitored during the study  for any  new onset AEs.
As with all therapeutic proteins, there is a potential for immunogenicit y with ranibizumab. In 
adult patients, the pretreatment incidence of immunoreactivit y to ranibizumab was 0% to 5%. 
After monthl y dosing with ranibizumab for 6 to 24mont hs, antibodies to ranibizumab were 
detected in approximately  1% to 9% of patients. The clinical significance of immunoreactivit y 
to ranibizumab is unclear. Among neovascular age-
related macular degeneration patients with 
the highest levels of immunoreactiv ity, some were noted to have iritis or vitritis. Intraocular 
inflammation was not observed in the retinal vein occlusion or diabetic macular edema patients 
with the highest levels of immunoreactivity . The number of administrations of ranibizumab in 
this study is less than that for the treatment of adult conditions. In addition, neonates have a less 
developed adaptive immune response (Adkins et al 2004). Hence, the potential risk of 
immunogenicit y in this study popula tion is likely  to be low.
An independent Data Monitoring Committee (DMC) wasestablished to monitor the safety  of 
the trial participants in the core stud y and will continue evaluations in this extension study  until 
the last patient has completed visit 301 (i.e. week 
[ADDRESS_387585] study treatment in the core 
study ) or discontinued the study  (see Section 8.4), to ensure that the trial is being conducted 
with the highest scientific and ethical standards, and make appropriate recommendations based 
on the data seen.
Epoch [ADDRESS_387586] of male and female preterm infants/children who have 
successfull y completed the CRFB002H2301 study.
4.[ADDRESS_387587] study  related procedure (including 
investigational treatment):
1. Signed informed consent from parent(s) or legal guardian(s), in compliance with local 
requirements
2.The patient successfully  completed the core study CRFB002H2301, as defined by  
[CONTACT_314898] [ADDRESS_387588]
3.The patient received study  treatment in both ey es at baseline o f study  CRFB002H2301

[COMPANY_001] Confidential Page 30
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
4.2 Exclusion criteria
Patients fulfilling any of the following criteria at study  entry are not eligible for inclusion in 
this study . No additional exclusions may  be applied by  [CONTACT_093], in order to ensure that 
the study  population will be representative of all eligible patients.
1.Patient has a medical condition or personal circumstance which precludes study  
participation or compliance with study procedures , as assessed b y the Investigator
2.Patient has been discontinued from the core study CRFB002H2301 at any  time
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
[IP_ADDRESS] Epoch 1
0.1mg and 0.2 mg ranibizumab
Ranibizumab solution for injection will be supplied (open label) in vials. Each vial contains 
ranibizumab in the concentration of 10mg/mL (RFB002 0.5mg/0.05 mL). Ranibizumab is 
formulated as a sterile solution aseptically  filled in a sterile glass vial for single use only. The 
content of the vial must not be split. The vials will be supplied by [CONTACT_314913].
Ranibizumab must be stored according to the label instructions and it must be kept in a secure 
locked facility .
Each vial will be labeled with the appropriate information. Medication labels will comply  with 
the legal requirements and will be printed in the local language. The storage conditions for study  
drug will be described on the medication label.
[COMPANY_001] will provide sufficient supplies of ranibizumab to allow for completion of Epoch 1.
Treatment administration is detailed in Section 5.5.4 of this protocol.
[IP_ADDRESS] Epoch 2
There is no investigational/ control drug in Epoch 2.
5.1.2 Additional treatment
No additional treatment is included in this trial.
5.2 Treatment arms
Treatment arm assignment will remain the same as in the core study .

[COMPANY_001] Confidential Page 31
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
5.3 Treatment assignment and randomization
At visit 201 (extension baseline), the investigator or his/her delegate will contact [CONTACT_105239]/exclusio n criteria. Treatment arm 
assignment and patient identifier will remain the same as in the core stud y.
During Epoch 1, the investigator or his/her delegate will contact [CONTACT_314914]. IRT will specify  a unique medicati on number for the package of 
study  drug to be dispensed to the patient.
The investigator must contact [CONTACT_105253]’s completion of Epoch 1.
5.4 Treatment blinding
This is an open -label study where the VA assessment at the child's 5thbirthday  visit will be 
performed by [CONTACT_314908]. The investigators, 
patients/parents/legal guardians and the Clinical Trial Team (CTT )are unmasked to the 
treatments administered during the core and extension studies. The measures defined inthe 
core study  CRFB002H2301 to minimize bias related to treatment knowledge will remain
implemented by [CONTACT_314915]. They will be provided 
in the Data Management Plan .
5.5 Treating the patient
5.5.1 Patient numbering
Each patient is uniquely  identified in the study  by a c ombination of his/her center number and 
patient number. The patient identifier will remain the same in the extension study as in the core 
study  CRFB002H2301. The investigator should contact [CONTACT_314916] (e.g. site transfer).
The investigator or his/her staff will contact [CONTACT_314917] I RT.
5.5.2 Dispensing the study drug
Each study site will be supplied by [CONTACT_314918] (open -label) study  drug.
The study  drug packaging has a 2-part label. A unique medication number (kit number) is 
printed on each part of this label. Investigator staff will identify  the study drug package(s) to 
dispense to the patient b y contact[CONTACT_314919](s).
Immediately  before dispensing the package to the patient, investigat or staff will detach the tear-
offlabel from the packaging and affix it to the source document (Drug Label Form) for that 
patient’s unique subject number.
5.5.3 Handling of study  and additional treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment (ranibizumab) must be received by a designated person at the study  site, 
handled and stored safely  and properl y, and kept in a secured location to which only the 

[COMPANY_001] Confidential Page 32
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
investigator and designees have access. Upon receipt, all study  treatment must be stored 
according to the in structions specified on the labels. Clinical supplies are to be dispensed only  
in accordance with the protocol. Technical complaints are to be reported to the respective 
[COMPANY_001] CPO Quality  Assurance.
Medication labels will be in the local language and co mply  with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the patient except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_314920] y and at the completion of the trial.
At the conclusion of the study , and as appropriate during the course of the study (e.g. after 
completion of Epoch 1),the investigator will return all unused study  treatment, packaging, drug 
labels, and a copy of the completed drug accountability  log to the [COMPANY_001] monitor or to the 
[COMPANY_001] address provided in the investi gator folder at each site.
[IP_ADDRESS] Handling of additional treatment
Not applicable.
5.5.4 Instructions for prescribing and taking study treatment
0.1mg and 0.2 mg ranibizumab
On day(s) when study  treatment is administered, all assessments must be conducted before 
administration except when specified otherwise in Section 6.
All study  treatment administration during the study  must be recorded in the Dose 
Administration Record eCRF.
Instructions on preparation of the aseptic field, preparation of the ranibizumab for injection, the 
intravitreal injection technique to minimize the risk of complications in patients, and 
information on pre -and post -injection procedures are provided in th
e study operation manual.
Treatment with ranibizumab (either as re-treatment after ranibizumab has alread y been inject ed 
in the same eye or as switch ranibizumab treatment from study  laser therapy  administered in 
the core study )will be permitted for eligi ble ey es up to and including the study  visit occurring 
[ADDRESS_387589] study treatment in the core study  CRFB002H2301 (Epoch 1). The 
following rules apply :
Treatment with investigational ranibizumab will only  be permitted for recurrence / 
worsenin g of ROP, as judged b y the investigator. Details (e.g. reason) must be 
documented in the CRF.
No further investigational ranibizumab treatment can be administered to the ey e after it 
wasswitched to study laser therapy (in the core study  CRFB002H2301) . If the other ey e 
was not switched to study laser therapy  (in the core study  CRFB002H2301) then this ey e 
could be administered ranibizumab re -treatment.

[COMPANY_001] Confidential Page 33
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
A maximum of 3 study  ranibizumab treatments can be administered to each ey e 
throughout the core and extensi on studies (i.e. including injections received in the core 
study  CRFB002H2301 and extension study  CRFB002H2301 E1).
The minimum time interval between ranibizumab injections in the same eye is 28 day s.
Only  the ey e which needs treatment will be treated. If both ey es need treatment, then both 
eyes will be treated.
Investigational r anibizumab is not to be administered to an ey e that has developed stage 4 
or 5 ROP. The development of an y complications of ROP, which is assessed by  [CONTACT_314921], should be managed as 
appropriate and the treatment given documented in the eCRF .
Investigational ranibizumab treatment must be discontinued for a patient under 
circumstances listed in Table 5-2.
No further investigational ranibizumab treatmen
t can be administered if the patient was 
discontinued from study treatment in the core study CRFB002H2301 .
The dose of stud y ranibizumab to be administered (if the above rules appl y) will be as follows:
Table 5-1 Study  ranibizumab dose in Extension study  based on treatment 
received at the baseline visit in core study  (CRFB002H2301)
Treatment received a t the baseline visit
in Core study (CRFB002H2301)Ranibizumab dose
in Extension study (CRFB002H2301 E1)
RBZ 0.1mg RBZ 0.1mg
RBZ 0.2mg RBZ 0.2mg
Laser RBZ 0.2mg
After treatment with investigational ranibizumab, the visits as per Additional Assessment 
Schedule in Table 6-2will be performed . All study  ranibizumab treatments must be recorded 
in the I RT s ystem.
Patients with recurrence / worsening of ROP, in the opi[INVESTIGATOR_41651], who are not 
eligible or suitable for treatment with ranibizumab should be treated with Standard of Care
therap y as per local clinical practice . Details of any treatments or procedures should be 
documented in the CRF.
5.5.5 Permitted dose adjustments and
interruptions of study  treatment
Investigational treatment dose adjustments and/or interruptions are not permitted.
5.5.6 Rescue medication
Patients with recurrence/worsening of ROP (as judged b y the investigator) who are not eligible 
or suitable for treatment with ranibizumab as per Section 5.5.[ADDRESS_387590] be recorded in the Concomitant medications or 
Surgical and medical procedures CRF as applicable.

[COMPANY_001] Confidential Page 34
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
5.5.[ADDRESS_387591] the patient’s parent(s) or legal guardian(s) to notify  the study  site 
about any new medications the 
patient takes since the patient completed the core study and 
throughout the extension study . All medications andprocedures (including physical therapy  and 
blood transfusions) administered when the patient was enrolled into the extension study  and 
after must be recorded in the prior and concomitant medications eCRF or the surgical and 
medical procedures eCRF as appropriate .
Concomitant medications which are ongoing at the time of the last visit in the core study 
CRFB002H2301 must be recorded, and entries in the extension study  database should match 
those in the core study  database as appropriate .
For patients whose baseline visit of the extension study  does not occur on the same day  as the 
last visit in the CRFB002H2301 core study , relevant medications and procedures (e.g. related 
to ocular treatment) which started after the last visit in the core study  and before the baseline
visit in the extension study will 
also be recorded.
Each concomitant drug and procedures must be individually  assessed against all treatment s in 
Table 5-2. Ifin doubt the investigator should contact [CONTACT_314922] a new medication to be started.
From Visit 301,
concomitant medication s/ non-drug therap iesrelated to common childhood 
infections and accidents/injuries if they arenotSAEs (Section 7.1) arenotrequired tobe 
reported in the CRF.
5.5.[ADDRESS_387592] visit 
in the core stud y
.
Table 5-
2 Treatment which prohibits further use of study ranibizumab
Medication Action to be taken
Any intravitreal anti -VEGF agent other than the 
investigational drugDiscontinue study treatment
Any system ic anti -VEGF agent Discontinue study treatment
Any other nonsurgical treatment of ROP Discontinue study treatment
Any surgical treatment of ROP (e.g. cr yotherapy, 
vitrectom y, laser)Discontinue study treatment
Any other investigational medicinal product as 
part of another clinical study, except vitamins 
and mineralsDiscontinue study treatment
Abbreviations: ROP –retinopathy of prematurity; VEGF –vascular endothelial growth factor
5.5.9 Emergency  breaking of assigned treatment code
Not applicable. This is an open-label stud y.

[COMPANY_001] Confidential Page 35
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
5.[ADDRESS_387593] of Care therapy  as per local clinical practice should be 
provided b y investigator and/or referring ph ysician based on patient availability  for follow -up.
5.6.2 Discontinuation of Study Treatment
Discontinuation of study  treatment for a patient occurs when study  drug is stopped earlier than 
the protocol planned duration (i.e. during Epoch 1), and can be initiated by  [CONTACT_314923] ’s 
parent(s) or legal guardian(s) or the investigator.
The investigator must discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would negativel y impact the risk/benefit of trial participation.
Study  treatment must be discontinued for a patient under the following circumstances:
Patient’s parent(s) or legal guardian(s) wish
Use of treatment as per Table 5 -2
Any situation in which study  treatment administration might result in a safety  risk to the 
patient
If discontinuation of study  treatment occurs, the patient should NOT be considered withdrawn 
from the study . The patient should return for assessments as described in Table 6-1. The 
investigator must determine the primary  reason for the patient’s premature discontinuation of 
study  treatment and recor d this information 
on the Dosage Administration eCRF.
After study  treatment discontinuation, all data should be collected as per Table 6-1and, at a 
minimum, in abbreviated visits, the following data shou
ld be collected at clinic visits or via 
telephone visits according to the stud y visit schedule :
new / concomitant treatments
Adverse Events/Serious Adverse Events
5.6.[ADDRESS_387594] the risk/benefit of the patient's participation in the trial. 
A final evaluation at the time of the patient’s study  withdrawal should be made as detailed in 
Table 6-
1. The investigator must also contact [CONTACT_105253]’s withdrawal from 
the study  if it occurs before the patient has completed the last visit in Epoch 1 and document 
the decision to withdraw the patient in the Study  Completion CRF and patient's source 
documents.

[COMPANY_001] Confidential Page 36
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
[IP_ADDRESS] Withdrawal of informed consent
Patient’s parent(s) or legal guardian(s) may voluntarily  withdraw consent for the patient to 
participate in the study  for any reason at any time. Withdrawal of consent occurs only when 
patient’s parent(s) or legal guardian(s):
Does not want the patient to participate in the study an ymore and
Does not allow further collection of personal data In this situation, the investigator should make 
a reasonable effort (e.g. telephone, e-mail, letter) to understand the primary  reason for the 
patient's parent(s) or legal guardian decision to withdraw his/ her consent tothe patient's 
participation and record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_102]’s parent(s) or legal guardian(s) are not allowed unless 
safet y findings require communicating o r follow -up.
A final evaluation at the time of the patient’s study  withdrawal should be made as detailed in 
Table 6-1. 
[COMPANY_001] will continue to keep and use collected study information according to appl icable law.
The investigator must also contact [CONTACT_105253]’s withdrawal from the study 
if it occurs before the patient has completed the last visit in Epoch 1 and document the patient's 
parent(s) or legal guardian(s) decision to withdra w consent in the Study  Completion CRF and 
patient's source documents.
5.6.4 Loss to follow -up
For patient s whose status is unclear because they fail to appear for study  visits and their parent(s) 
or legal guardian(s) have not statedan intention to discontinue or withdraw their child, the 
investigator should show "due diligence" by [CONTACT_314924]’s parent(s) or legal guardian(s) , e.g. dates of telephone calls, registered 
letters , etc.
5.6.5 Early  study termination by  [CONTACT_18620]. This may  include reasons 
related to the benefit risk assessment of participating in the study , practical reasons, or for 
regulatory  or medical reasons (including slow enrolment). Should this be necessary, the patient 
must be seen as soon as possible and treated as a prematurel y withdrawn patient. The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator will 
be responsible for informing the Institutional Review Board/Independent Ethics Committee 
(IRBs/IECs) of the early  termination of the trial.
[ADDRESS_387595] all study  related assessments and indicate with an “x” when the 
visits are performed. When a visit as per the additional assessment schedule coincides with a 

[COMPANY_001] Confidential Page 37
Amended Protoc ol Version v02 (Clean ) Protocol No. CRFB002H2301E1
visit as per the main assessment schedule, assessments have to be performed as per the main 
assessment schedule. Non study -related assessments and follow -ups which are performed 
according to local medical prac ticeshould not be considered as unscheduled study  visits.
Patients/subjects should be seen for all visits on the designated day, or as close to it as possible 
(visit window as indicated on the relevant assessment schedule tables should be considered). 
Alternativel y, Visit304 may be conducted remotely  by [CONTACT_648], at the investigator’s discretion. 
Study  visit assessments should be carried out on the same day. If required , assessments may be
conducted on two consecutive days, in order to decrease patient burden . Missed visits should 
bere-scheduled as soon as possible. Missed or rescheduled visits should not lead to automatic 
discontinuation. Patients/subjects who prematurely discontinue the stud y for an y reason should 
be scheduled for a visit as soon as possible, at which time the assessments listed for Visit 399
(final visit )will be performed
unless otherwise specified . 
Patient’s parent(s) or legal guardian(s) will be contact[CONTACT_15025] y evaluations during the [ADDRESS_387596] study  visit (se e Section 7.2 ).

[COMPANY_001] Confidential Page 38
Amended Protocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Table 6-1 Main A ssessment Schedule
Epoch 1
(Post -treatment follow -up 1)Epoch 2
(Post -treatment follow -up 2)
Visit 201a
(baseline)202 203 301 302 303 304 399 incl. 
premature 
withdrawalSupplemental 
visit n
Timepoint 
(referring to the 
Day 1 in the study  
CRFB002H2301)Day of the 
patient’s last visit 
in core 
CRFB002H2301aWeek 32
(+/-1 
week)Week 40
(+/-1 week)Week 52
(+/-2 weeks)Child’s 2 years’ 
corrected agei
(+/-4 weeks)Child’s 3 years’ 
corrected agei
(+/-4 weeks)Child’s 4th
birthdayj
(+/-4 weeks)Child’s 5th
birthdayj
(+/-12 weeks)
Obtain informed 
consentX
Inclusion/Exclusion X
Demography X
Relevant medical 
conditionsXc
Adverse events XbX X X X X X X X
Concomitant 
medication useXdX X X X X X X X
Health status 
(respi[INVESTIGATOR_314878])X X
Hospi[INVESTIGATOR_314879] X X X X X X X X
Blood pressure X
Height, weight X X
Head 
circumferenceX
Laboratory tests X

[COMPANY_001] Confidential Page 39
Amended Protocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Epoch 1
(Post -treatment follow -up 1)Epoch 2
(Post -treatment follow -up 2)
Visit 201a
(baseline)202 203 301 302 303 304 399 incl. 
premature 
withdrawalSupplemental 
visit n
Timepoint 
(referring to the 
Day 1 in the study  
CRFB002H2301)Day of the 
patient’s last visit 
in core 
CRFB002H2301aWeek 32
(+/-1 
week)Week 40
(+/-1 week)Week 52
(+/-2 weeks)Child’s 2 years’ 
corrected agei
(+/-4 weeks)Child’s 3 years’ 
corrected agei
(+/-4 weeks)Child’s 4th
birthdayj
(+/-4 weeks)Child’s 5th
birthdayj
(+/-12 weeks)
Ocular 
examinationeX X X X X
Fundus 
examination by 
[CONTACT_314925] X X X X
Ocular and visual 
function XmXmXg,qXo
Epoch 1 
dispositionfX
Study disposition X
a –Visit 201 (baseline) of CRFB002H2301 E1can occur on the same day as the patient’s last visit in CRFB002H2301 (i.e. on Day 169 / Visit [ADDRESS_387597] of the additional assessments visit as per protocol in CRFB002H2301 ). b -Adverse Events which are ongoing at the 
patient’s l ast visit in CRF002H2301 and at the baseline visit in the extension study must be recorded and entries in the extension study database 
should match those in the core study database as appropriate.

[COMPANY_001] Confidential Page 40
Amended Protocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Epoch 1
(Post -treatment follow -up 1)Epoch 2
(Post -treatment follow -up 2)
Visit 201a
(baseline)202 203 301 302 303 304 399 incl. 
premature 
withdrawalSupplemental 
visit n
Timepoint 
(referring to the 
Day 1 in the study  
CRFB002H2301)Day of the 
patient’s last visit 
in core 
CRFB002H2301aWeek 32
(+/-1 
week)Week 40
(+/-1 week)Week 52
(+/-2 weeks)Child’s 2 years’ 
corrected agei
(+/-4 weeks)Child’s 3 years’ 
corrected agei
(+/-4 weeks)Child’s 4th
birthdayj
(+/-4 weeks)Child’s 5th
birthdayj
(+/-12 weeks)
c -Whenbaseline visit of the extension study does not occ ur on the same day as the last visit in the core study, relevant medical conditions which 
started and/or ended after the last visit in the core and before the baseline visit in the extension study will be recorded ( see Section 6.2 ).
d –Concomitant medications which are ongoing at the patient’s last visit in CRF002H2301 must be recorded and entries in the exte nsion study 
database should match those in the core study database as appropriate. For patients wh ose baseline visit of the extension study does not occur on 
the same day as the last visit in the CRFB002H2301 core study, relevant medications and procedures which started after the la st visit in the core 
study and before the baseline visit in the extensi on study will also be recorded (see Section 5.5.7 ).
e -Including examination of the anterior segment and lens
f -To be recorded once upon Epoch 1 completion
g -Will not be performed in case of patient’ s premature withdrawal
h -To be recorded once upon first hospi[INVESTIGATOR_314880]
i –Visit should be scheduled as close as possible when child reaches this corrected age
j –Visit should be scheduled as close as possible to the child’s appropriate birthday
m -Assessment of presence/ absence of  refraction. See 
Section 6.4.2 .
n –The supplemental visit should take place as early as possible after the protocol amendment is implemented. If the date of this visit is within 2 
months prior the next scheduled visit, then this supplemental visit may be delayed and performed with the next scheduled visi t
p –ETDRS visual acuity test (using Lea s ymbols) to be performed by a masked VA assessor : See Section 6.4.3.
q –Inclu des assessments (m)and vision function form (peripheral vision).

[COMPANY_001] Confidential Page 41
Amended Protocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Table 6-2 Additional A ssessment Schedule – Treatment with Ranibizumab
Visit 29y1f29y2f29y3f29y4f
Days after ranibizumab treatmenta
(visit window)0 3
(-2day/+1 day)7
(±2day)14b
(±4days)
Adverse events X X X X
Concomitant medication use /Surgical and 
medical proceduresX X X X
Ocular examinationcXdX X X
Fundus examination XdX X X
Administer ranibizumabeX
a –Up to 2 re -treatments (including treatments administered in the Core Study )are allowed for each eye if required
b –After this visit, the patient resumes the next visit according to their original Main Assessment Schedule
c –Includes examination of the anterior chamber and lens
d –Assessments to be conducted before administration of ranibizumab treatment
e –Theranibizumab treatment dose will be as per Table 5 -1
f –y is the number corresponding to the ranking of the post- baseline treatment, continuing from the core (e.g. 1 corresponds to the 1sttreatment after 
the core study baseline treatment )

[COMPANY_001] Confidential Page 42
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
6.1 Information to be collected on screening failures
Not applicable. There is no screening Epoch.
6.2 Patient demographics/other baseline characteristics
Patient demographic and baseline characteristic data to be collected on all patients include: race 
and ethnicit y (based on that of the mother), start date of the mother’s last normal menstrual 
period, sex, year of birth, gestational age at birth (by [CONTACT_181122]). Entries in the extension 
study  data base should match those in the core study  database.
For patients whose baseline visit of the extension study  does not occur on the same day  as the 
last visit in the CRFB002H2301 core study , relevant medical condition which started and/or 
ended after the last visit in the core study  and before the baseline visit in the extension study 
will be recorded in the extension study  database .
6.3 Treatment exposure and compliance
Every  time that ranibizumab treatment is to be administered, I RTneeds to be contact[CONTACT_5365] t he 
medication (kit) number. Information regarding investigational treatment administration will be 
collected in the Dose Administration Record in the eCRF.
Exposure to ranibizumab treatment will be based on the number of injections by [CONTACT_314926] 
(as databased on IRT as well as on the Drug Administration Record eCRF). Compliance with 
ranibizumab treatment will be assessed by [CONTACT_314927] [ADDRESS_387598] ophthalmoscopy  in 
both ey es by  [CONTACT_314928] 6-1 and Table 6 -2:
Features of active ROP disease:
ROP disease 
–zone, stage, extent by  [CONTACT_314900], and characteristics of vascular 
changes of plus disease (extent by  [CONTACT_314929] y) (up to Visit 301 included)
Extra -retinal vessels extending from the retina into the vitreous and judged to be a 
sign of active ROP disease (up to Visit 301 included)
Features of late sequelae of ROP /ocular structural abnormalities:
Retrolental membrane obscurin g the view of the posterior pole
Substantial temporal retinal vessel dragging causing abnormal structural features
Posterior retinal fold involving the macula
Retinal detachment involving the macula
Retinal detachment not involving the macula
Pre-retinal f ibrosis
Optic disc pallor (from Visit 301 included onwards)

[COMPANY_001] Confidential Page 44
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
6.4.[ADDRESS_387599] been used in previous studies assessing treatments for ROP (Cryotherapy  for 
Retinopathy  of Prematurity  Cooperative Group 1988, Good 2004, Mintz -Hittner et al 2011 ).
Ocular and visual function assessments and VA assessment are standard visual function 
assessments (Kvarnström 2005, Becker 2002 )
.
6.5 Safet y
6.5.1 Ocular examination
The presence of fundus features abnormalities will be assessed in both eyes at study  visits 
described in Section 6.4.1 ).
Ocular examination of structures in addition to that of the fundus will be performed in both eyes, 
including assessment of anterior ocular structures and the lens , described in Table 6-1.
Clinically  significant abnormal findings will be reported as AEs in the CRF except for specific 
events as defined in Section 7.1.
6.5.2
Vital signs
[IP_ADDRESS] Blood pressure
No Blood Pressure measurement is required to be performed by [CONTACT_760]. I nstead, the most 
recent systolic and diastolic blood pressure [mm Hg] measured as part of the routine clinical 
care should be recorded in the eCRF at visits specified in Table 6-1.
Information must be included in the source documentation at the study  site. Significant findings 
which meet the definition of an Adverse Event must be recorded on the Adverse Event CRF.
[IP_ADDRESS] Standing height, sitting height, weight and head circumfer ence
For the assessment of standing/sitting heights, weight and head circumference, the patient 
should be wearing minimal clothing (e.g., a clean diaper if applicable and undershirt). Study 
staff trained in the assessment of infants or children will perfor m these assessments as 
applicable.
Standing and sitting height in centimeters will be measured using a stadiometer or according to 
local clinical practice. Leg length will be derived from the difference between standing height 
and sitting height.
Body weig ht will be measured using an electronic scale or according to local clinical practice.
The maximum occipi[INVESTIGATOR_314881] a tape 
measure.

[COMPANY_001] Confidential Page 45
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
6.5.3 Health status
[IP_ADDRESS] Respi[INVESTIGATOR_314882]’ respi[INVESTIGATOR_314883] 6-1by [CONTACT_314930], frequency  and severity  of wheezing 
symptoms in the last 12 months .
[IP_ADDRESS] Hearing function status
Patient’s hearing function status assessment will include the presence of hearing impairment 
and the use of hearing aids. Usual hearing (normal or near normal; hearing loss corrected with 
aids (moderate or severe); hearing loss not corrected with aids (profound); no useful hearing 
even with aids) will be assessed.
[IP_ADDRESS] Hospi[INVESTIGATOR_314884] (from birth to first
hospi[INVESTIGATOR_314880]) and weight at the first 
discharge from hospi[INVESTIGATOR_314885], only if not alread y record ed during the core 
study .
6.5.4 Laboratory  evaluations
No laboratory  evaluations are required per protocol (e.g., hematology , clinical chemistry  or 
urinaly sis). However, d ata from tests which were performed as part of routine clinical practice 
will be collected. At visits specified in Table 6-1,the most recent laboratory values for the tests 
below will be collected on the eCRF, where such data are available.
[IP_ADDRESS] Hematology
Hematology
 will include he moglobin (Hb), white cell count (WCC) and platelet count (PLT).
[IP_ADDRESS] Clinical chemistry
Serum chemistry  data will include urea and electroly tes (sodium, potassium, creatinine and 
urea/blood urea nitrogen (BUN)) and liver function tests (bilirubin, albumin, total protein, 
aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP)).
[IP_ADDRESS] Urinaly sis
Urinaly sis will include urine protein.
6.5.[ADDRESS_387600] for this patient population.

[COMPANY_001] Confidential Page 46
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
7 Safety  monitoring
7.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after parent(s)/ legal guardian(s) provided written informed 
consent for their child’s participation in the study until the end of stud y visit. Therefore, an AE 

[COMPANY_001] Confidential Page 47
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
may or may not be temporally  or causall y associated with the use of a medicinal (investigational) 
product.
In this study , the following safety events will be collected as study  endpoints only  and are not 
to be additionally  recorded as an AE or SAE. These specific events are captured on the endpoint 
page of the eCRF only, and investigators must not report these on an AE/SAE page of the eCRF:
Substantial temporal retinal vessel dragging causing abnormal structural features/ macular 
ectopia
Retrolental membrane obscuring the view of the posterior pole
Posterior retinal fold involving the macula
Retinal detachment
Pre-retinal fibrosis
Optic disc 
pallor (from Visit 301 included onwards)
Optic disc swelling (from Visit 301 included onwards)
Pi[INVESTIGATOR_314877] (from Visit 301 included onwards)
Atrophic changes in macula (from Visit 301 included onwards)
In this study , from Visit 301, common childhood infections and accidents/ injuries are not 
required to be reported as AEs, unless the AE meets one o f the serious criteria (SAEs) ( Section 
7.2.1 ).
All other AEs and SAEs, whether or no t considered related to ranibizumab by  [CONTACT_093], 
must be reported.
The occurrence of adverse events must be sought by  [CONTACT_105]-directive questioning of the patient ’s 
parent(s) or legal guardian(s) at each visit during the study . Adverse events also may be detected 
when they are volunteered by [CONTACT_102]’s parent(s) or legal guardian(s) during or between 
visits or through ph ysical examination findings, laboratory  test findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms,
they are con sidered clinically significant,
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_18532]. Investigators have the responsibility  for managing the safet y of individual 
patient and identify ing adverse events.
Adverse events must be recorded in the Adverse 
Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  [CONTACT_6644]:
Severity grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities

[COMPANY_001] Confidential Page 48
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
severe: prevents normal activities
Site (non- ocular/ocular) an dlateralit y (bilateral /left ey e/right ey e), if an ocular AE
Relationship to the study  treatment and to the study  procedure (e.g. intravitreal injection)
Duration (start and end dates) or if the event is ongoing an outcome of not recovered/not 
resolved or recovering/resolving must be reported
Whether it constitutes a serious adverse event (SAE - s ee Section 7.2 for definition of 
SAE)
If it constitutes an SAE (see Section 7.2 for definition of SAE) , seriousness criteria (e.g. 
death, requires or prolongs hospi[INVESTIGATOR_059])
Action taken with investigational treatment. All adverse events must be treated 
appropriatel y. Treatment may include one or more of the following: no action taken (e.g.,
further observation only )/temporarily
 interru pted/ permanentl y discont inued due to this 
adverse event/unknown/not applicable
Medicat ions or therapi[INVESTIGATOR_32546] (no c oncomitant medication or non-drug therapy / 
concomitant medication or non
-drug therap y)
Outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent, and assessment must be made at each visit (or more frequently , if necessary ) of 
any changes in severity, the suspected relationship to the study drug , the interventions required 
to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the informed 
consent and should be discussed with the patient ’s parent(s) or legal guardian(s) during the 
study  as needed. Any new information regarding the safet y profile of the medicinal product that 
is identified between IB updates will be communicated as appropriate, for example, via an 
Investigator Notification or an Aggregate Safet y Finding. New information might require an 
update to the informed consent and has then to be discussed with the patient ’s parent(s) orlegal 
guardian(s) .
The investigator must also instruct each patient ’s parent(s) or legal guardian(s) to report any 
new adverse event (beyond the protocol observation period) that the patient ’s parent(s) or legal 
guardian(s) , or the patient’s personal physician, believes might reasonabl y be related to study 
treatment. Thi s information must be recorded in the investigator’s source documents; however, 
if the AE meets the criteria of an SAE, it must be reported to [COMPANY_001].
7.2 Serious adverse events
7.2.1 Definition of SA E
An SAE is defined as any adverse event [appearance of (or wors ening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
is fatal or life -threatening 

[COMPANY_001] Confidential Page 49
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this incl udes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a nSAE refers to a reaction in which the patien t was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex I V, ICH-
E2D Guideline).
Medical and scientific judgment should be exercised in deciding whethe r other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_121895] (see A nnex IV, ICH -E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
In this study , the safet y events listed in Section 7.[ADDRESS_387601] not report these on an AE/SAE page 
of the eCRF .
7.2.2 SAE repo rting
To ensure patient safet y, every  SAE, regardless of causalit y, occurring after the patient ’s 
parent(s) or legal guardian(s) has provided informed consent and until [ADDRESS_387602] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. An y SAEs experienced after 
the 30 day period should only be reported to [COMPANY_001] if the investigator suspects a causal 
relationship to study  treatment.

[COMPANY_001] Confidential Page 50
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_30755] [ADDRESS_387603] be reported separatel y as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form ;all applicable sections of the form must be completed in order to provide a clinically 
thorough report . The investigator must assess the relationship of each SAE to each specific 
component of study  treatment (if study  treatment consists of several compone nts),complete the 
SAE Report Form in English, and submit the completed form within [ADDRESS_387604] be reported as a follow -up to that event 
regardless of when it occurs. The f ollow -up information should describe whether the event has 
resolved or continues, if and how it was treated, whether the blind was broken or not and 
whether the patient continued or withdrew from study  participation. 
If the SAE is not previously documented in the Investigator ’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study treatment a Drug Safety and Epi[INVESTIGATOR_176078] y 
Department associate may urgentl y require further information from the investigator for health 
authority  reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and 
reported to the competent authorities and relevant ethics committees in accordance with EU 
Guidance 2011/C 172/01 or as per national regulatory requirements in participating countries.
In this study , safety events that are collected as study  endpoints will not be recorded as SAEs 
and do not follow the above expedited reporting process (Section 7.2.1). These events will be 
monitored and reviewed regularl y by [CONTACT_314931] .
7.3 Reporting of study  treatment errors
Medi cation errors are unintentional errors in the prescribing, dispensing, 
administration or 
monitoring of a medicine while under the control of a healthcare professional, patient / parent(s)/ 
legal guardian(s) or consumer (EMA definition).
Study  treatment erro rs and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety onl y if associated with an SAE.
Treatment error 
typeDocu ment in Dose 
Administration 
(DAR) eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE

[COMPANY_001] Confidential Page 51
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
8 Data revie w and database management
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and CRFs with the investigators and their staff. During 
the study , [COMPANY_001] employ s several methods of ensuring protocol and GCP compliance and the 
quality /integrity  of the sites’ data. The field monitor will visit the site to check the completeness 
of patient records, the accuracy  of entries on the eCRFs, the adherence to the protocol and to 
Good Clinical Practice, the pro gress of enrollment, and to ensure that study  treatment is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during the se visits. Continuous remote monitoring of each 
site’s data may be performed by a centralized [COMPANY_001] CRA organization . Additionally , a 
central analy ticsorganization may analyze data, identify  risks andtrends for site operational 
parameters, and provide reports to [COMPANY_001] Clinical Teams to assist wit h trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information in the e CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed b y the 
patient ’s parent(s) or legal guardian(s) (a signed copy is given to the patient ’s parent(s) or legal 
guardian(s) ).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. [COMPANY_001] ’monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation 
of SAEs and of data that will be used for all primary  variables. Additional checks of the 
consistency  of the source data with the eCRFs areperformed according to the study -specific 
monitoring plan. No information in source documents about the identity  of the patients will be 
disclosed.
8.2 Data collection
Designated investigator staff will enter the data required by [CONTACT_109051]/RDC 
system. Designated investigator site staff will not be given access to the s ystem until they have 
been trained.
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by [CONTACT_105273], allow the data to be confirmed 
or corrected online by [CONTACT_105274]. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigat or will receive copi[INVESTIGATOR_314886].
8.[ADDRESS_387605] the site personnel to make any  required corrections or 

[COMPANY_001] Confidential Page 52
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
additions. Queries are sent to the investigational site using an electronic data quer y. Designated 
investigator site staff is required to respond to the query  and confirm or correct the data .
Concomitant medications entered into the database will be coded using the World Health 
Organization ( WHO )Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical (ATC) classification system. Concomitant procedures, non-drug therapi[INVESTIGATOR_314887] (MedDRA) 
terminology .
Randomization codes and data about all study  drug(s) dispensed to the patient will be tracked 
using an Interac tive Response Technology  (IRT) during Epoch 1. The system will be supplied 
by a vendor, who will also manage the database. The database will be sent electronically  to 
[COMPANY_001].
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has beendeclared to be complete and accurate , it will be 
locked. Any changes to the database after that time can only be made after written agreement 
by [CONTACT_109053].
8.4 Data Monitoring Committee
An independent DMC (e.g. DMC involved in the core study  CRFB002H2301) will be 
established to monitor the safet y of the trial participants, toensure that the trial is being 
conducted with the highest scientific and ethical standards, and make appropriate 
recommendations based on the data seen .
The DMC charter will include the DMC membership and responsibilities, the timing of DMC 
meetings, the content of the analysis report for the DMC meetings, and the communication with 
the Sponsor. The DMC will only make recommendations for changes in study  conduct. The 
DMC will operate until the last patient has completed visit 301 (i.e. week 52 after the 1ststudy
treatment in the core study) or discontinued the study  whichever is the earliest.
8.5 Adjudication Committee
Not required.
9 Data analy sis
The statistical anal ysis will be performed or directed by  [CONTACT_314932].
Three planned anal yses will be performed in this study ; two interim analy ses (see Section 9.7 ) 
and one final analy sis at the completion ofthe study . Additional interim analyses may be 
conducted on safet y or efficacy  data as required. Further technical details and discussions of the 
statistical considerations for each will be provided in the appropriate Statistical Anal ysis Plan 
(SAP), which will be finalized prior to first patient first visit (FPFV).
Descriptive statistics (mean, median, standard deviation, lower quartile (Q1), upper quartile 
(Q3), minimum, and maximum) will be presented for continuous variables. The number and 
percentage of patients in each category  will be presented for categorical variables.

[COMPANY_001] Confidential Page 53
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
There are three treatment groups defined by[CONTACT_314933] y:
0.2 mg Ranibizumab group 
0.1 mg Ranibizumab group 
Laser treatment group 
All results will be displayed by [CONTACT_314934]. If appropriate, within each of 
these three treatment group s, analyses may also be conducted separately for patients who 
received monotherap y or who switched treatment (by [CONTACT_314935] e or b y patient as applicable).
Two baselines are defined ;the core baseline and the extension baseline. The core baseline will 
be the baseline of the core study . For statistical purposes, the last available non- missing values 
collected in study  CRFB002H2301 or CRFB002H23 01E1 prior to or on visit 201 will be 
considered to be extension baseline values. Core baseline will be used as baseline for both 
efficacy  and safet y analyses. The extension baseline will be used for demographic summary of
the extension study .
9.1 Analysis set s
The Extension Safety  Set for this study  is defined as the subset of the Safety  Set of the study 
CRFB002H2301 who enter sthis study .
All analyses will be carried out on the Extension Safet y Set and displayed by [CONTACT_314936] y unless otherwise specified.
9.2 Patient demographics and other baseline characteristics
Demographic information will be summarized for each treatment group and for all patients 
(total).
Relevant medical history  and current medical conditions using the core baseline will be 
tabulated by [CONTACT_9313] (arranged alphabetically ) and preferred term (arranged by 
[CONTACT_314937] 0.2 mg treatment arm) according to the latest version 
of MedDRA. Separate tables will be presented for ocular and non-ocular histories and 
conditions.
The same approach will be used for such data collected after the last visit in the core study 
CRFB002H2301 and before the baseline visit in th
isextension study  (Section 6.2 ).
ROP disease status will be defined as the value derived in the study  CRFB002H2301.
9.3 Treatments (study  drug, rescue medication, other concomitant 
therapi[INVESTIGATOR_014], compliance)
Expo sure to investigational treatment will be presented by [CONTACT_1570]. 
Patient disposition and reasons for discontinuation of study  medication and discontinuation of 
study  will be summarized by  [CONTACT_314938].

[COMPANY_001] Confidential Page 54
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Concomitant therapi[INVESTIGATOR_314888]  (CRFB002H2301 ) and the extension 
study  will be summarized by [CONTACT_314939]. 
9.4 Analysis of the primary  variable(s)
9.4.1 Variable(s)
The primary  efficacy  variable is the visual acuit y (VA) in the better -seeing ey e at the patient’s 
fifth birthday  as recorded by  [CONTACT_093].
9.4.2 Statistical model, hypothesis, and method of analy sis
If the primary  hypothesis testing in the core study  shows statistical signifi
cance , theprimary 
objective of the extension study will beassessed by [CONTACT_314940] y of ranibizumab 0.2 
mg to laser as follows: 
H01: µ0.2 mg Ranibizumab - µLaser= 0 versus H A1: µ0.2 mg Ranibizumab - µLaser≠ 0
where μTreatment Group is the unknown mean VA in the better -seeing eye at the fifth birthday  of 
patients in the relevant treatment group.
The hypothesis will be tested by [CONTACT_314941] 
(ANOVA) using the 
Cochran -Mantel -Haenszel (CMH) test with the observed VA values as scores as the response 
variable and the treatment group as the factor (with levels 0.2 mg ranibizumab and laser) . 
Stratification will be based on the ROP zone at the core study  baseline. Superiority  of 
ranibizumab 0.2 mg over laser will be concluded if the hypothesis H01 is rejected at the two-
sided 5% significance level and μ Ranibizumab 0.2 mg > μ Laser. 
If the primary  hypothesis testing in the core study does not show statistical significance , only 
descriptive st atistics (i.e., point estimate, and the 95% confidence interval) will be provided for 
the comparison between ranibizumab 0.[ADDRESS_387606] ANOVA using VA as the response variable andtreatment 
group and zone as factors will be performed. Two-sided 95% confidence intervals, assuming 
normality , will be produced for the VA within each treatment arm and the difference in VA 
between a pair of treatment arms will be calculated from least squares means. No p -values will 
be disp
layed for this analy sis.
Note that µ 0.2 mg Ranibizumab is estimated using those patients that received 0.2 mg ranibizumab at 
baseline in the core stud y CRFB002H2301. This includes patients that received laser treatment 
at a later date in either the core or extension study . Patients that permanently  discontinue 
treatment with 0.2 mg ranibizumab are a lso included. However, pat ients for which the value of 
the primary  variable is missing are excluded (see Section 9.4.3). A similar approach is taken for 
the 0.1 mg ranibizumab arm.
Similarly , 
µLaseris estimated using those patients that received laser at baseline in the core study 
CRFB002H2301. This includes patients that received 0.2 mg ranibizumab treatment at a later 
date in either the core or extension study . Patients that permanentl y discontinue treatment with 
laser are also included. However, patients for which the value of the primary variable is missing
are excluded (see Section 9.4.3 ) .

[COMPANY_001] Confidential Page 55
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
9.4.3 Handling of missing values/censoring/discontinuations
Missing data will not be imputed for the primary  efficacy  analy sis. Hence, as stated in Section 
9.4.2, the analy sis of the primary  variable is only conducted for patients with a non-missing 
value for VA .
9.4.4 Sensitivity analy ses
The primary  variable will also be assessed by [CONTACT_314942] e study .
Additional analy ses may be conducted for patients who switch treatment and patients who do
notswitch trea tment . 
Additional analyses may be conducted forpatients who receive a medication which prohibits 
further use of ranibizumab or study  laser . These analy ses will be specified in t he SAP.
9.5 Analysis of secondary  variables
The analyses for objectives which areassessed up to a particular time (e.g. up to the patient’s 
fifth birthday ) will include data collected in both the core and extension studies.
No multiplicity  adjustment will be used for the analy sis of secondary  variables. 
No imputation of missing data will be used for the analysis of secondary  variables unless 
specified in a scoring manual or similar.
Hence the analy sis of all secondary  variables will be based on the non -missing observations of 
patients that have not received a medication which prohibits further use of ranibizumab or study  
laser but may  have permanently  discontinued study
 treatment for another reason . 
9.5.1 Efficacy  variables
Continuous variables:
If the primary  hypothesis testing of the core study  shows statistical significance , the following 
objectives will be tested for the continuous variables below by [CONTACT_314943]. 
The superiorit y of ranibizumab 0.[ADDRESS_387607] to the VA of the better -seeing eye 
at the patient’s fifth birthday  
The superiorit y ofranibizumab 0.[ADDRESS_387608] to the VA of 
the better -seeing ey e at the patient’s fifth birthday 
The three superiorit y tests comparing pairs of treatment arms will be repeated with regard 
to the VA of t he worse -seeing ey e at the patient’s fifth birthday
Binary variables:
The absence of all ocular structural abnormalities (see Section 3.5.2 for the definitions) at 
or before the patient’s 2 y ears co rrected age and fifth birthday .
The recurrence of ROP up to [ADDRESS_387609] baseline visit in the core study
The absence of active ROP at [ADDRESS_387610] baseline visit in the core study

[COMPANY_001] Confidential Page 56
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
The CMH test with ROP Zone as assessed at the baseline of the core study  as stratification 
factor will be used for inference concerning binary secondary  efficacy  variables. However, the 
test will be based on proportions rather than a stratified ANOVA using the VA as a score. 
Mantel -Haenszel odds ratios and their two-sided 95% confidence intervals will be presented. 
Superiority  will be defined as a rejection of the null hypothesis (equalit y of proportions) and 
the Mantel -Haenszel odds ratio is in favor of the hy pothesized superior treatment.
Other efficacy variables:
Descriptive 
statistics will be provided for these effic acy variables by  [CONTACT_2939]:
The absence of all ocular structural abnormalities (see Section 3.5.1 for the definitions) at
or before [ADDRESS_387611] baseline visit in the core study
Therecurrence of ROP up to 40weeks post baseline visit in the core study
The absence of active ROP at [ADDRESS_387612] baseline visit in the core study
The absence of each ocular structural abnormalit y considered individuall y (see Section 
3.5.2 for the definitions) at or before the patient’s 2 y ears’ corrected age and at or before 
the patient’s fifth birthday
The number of ranibizumab injections received in the treatment of patients with ROP up to 
and including 
[ADDRESS_387613] baseline visit in the core study by [CONTACT_314926] 
At the patient’s 2 years corrected age and fifth birthday 
The refraction in each eye: Refractive error will be categorize d into my opia (spherical 
equivalent of 0.25 diopters or more of m yopia) and high m yopia (spherical equivalent 
of 5.00 diopters or more of my opia). The percentage of patients without myopia, with 
myopia, and with high my opia will be display ed. 
9.5.2 Safety  variables
Safety  analyses will be assessed by [CONTACT_314944] -
emergent AEs by [CONTACT_14459]. Adverse events (overall AE, ocular AE, non-ocular AE) will be presented by [CONTACT_314945] (arranged alphabeticall y) and preferred term (arrang ed by [CONTACT_314946] 0.2 mg treatment arm) using the most recent version of MedDRA 
available. Patients who experienced multiple AEs for a preferred term will be counted once, 
similarly  for patients with multiple AEs per sy stem orga n class.
All other information collected (e.g., severity , relationship to study  procedures and study
treatment, leading to permanent study /study  treatment discontinuation, and deaths) will be 
tabulated and listed as appropriate.
The number of hospi[INVESTIGATOR_24509]/ prolongations of hospi[INVESTIGATOR_314889].
Deaths, SAEs, and AEs leading to permanent discontinuation of study treatment will be listed 
separately and, if appropriate, summarized by  [CONTACT_314947] m.
Unless otherwise specified, AE data from the first study  treatment in the core study  will be 
included in all AE analyses. Vital signs, requirement for respi[INVESTIGATOR_314890] (if appropriate) by [CONTACT_3232]. 

[COMPANY_001] Confidential Page 57
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Other safety  data will be summarized and listed as appropriate.
9.7 Interim analy ses
Two interim analy ses will be performed by [CONTACT_314948] (see Section 3.5 for more details).

[COMPANY_001] Confidential Page 59
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
9.8 Sample size calculation
The sample size calculation is not based on a power calculation. The number of patients enrolled 
in this study  depends on the number of patients in the core study  fulfilling the eligibility criteria 
of the extension study  (see Section 4).
10 Ethical considerations
10.1 Regulatory  and ethi cal compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/ EC, US CFR 
21, and Japanese 
Ministry  of Health, Labor, and Welfare), and with the ethical principles laid down in the 
Declaration of Helsinki.
10.2 Informed consent procedures
Eligible patients may only be included in the study  after their parent(s) or legal guardian(s) have 
provided written (witnessed, where required by [CONTACT_6617]), IRB/IEC -approved informed 
consent. Informed consent must be obtained before conducting any study -specific procedures 
(e.g. all of the procedures described in the protocol). The process of obtaining informed consent 
must be documented in the patient source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory  requirement s and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_314949]/IE C, and a copy  of the 
approved version must be provided to the [COMPANY_001] monit or after IRB/ IEC approval.
10.3 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the tr ial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to the patient ’sparent(s) or 
legal guardian(s). Prior to study  start, the investigato r is required to sign a protocol signature 
[CONTACT_5389]/her agreement to conduct the study  in accordance with these documents 
and all of the instructions and procedures found in this protocol and to give access to all relevant 
data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Qualit y Assurance representatives, 
designated agents of [COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an 
inspection of the clinical site is requested by a regulatory  authorit y, the investigator must inform 
[COMPANY_001] immediately  that this request has been made.
10.4 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report the 

[COMPANY_001] Confidential Page 61
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Connolly  BP, Ng EY, McNamara JA, et al [2002] A comparison of laser photocoagulation with 
cryotherap y for threshold retinopathy  of prematurity  at 10 years: Part 2. Refractive outcome. 
Ophthalmology ; 109(5):936 -41.
Cryotherapy  for Retinopathy  of Prematurity  Cooperative Group [1988] Multicenter trial of 
cryotherap y for retinopathy  of prematurit y. Preliminary results. Arch Ophth almol; 106(4):471 -
9.
Darlow BA, Ells AL, Gilbert CE, et al [2013] Are we there yet? Bevacizumab therapy  for 
retinopathy  of prematurity . Arch Dis Child Fetal Neonatal Ed; 98(2):F170 -4.
De Pasquale MD, Pessolano R, Boldrini R, et al [2011] Continuing respons e to subsequent 
treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell 
carcinoma. J Pediatr Hematol Oncol; 33(5):e176 -9.
Edward DP, Kaufman LM [2003] Anatomy , development, and physiology  of visual system. 
Pediatr. Clin North Am; 50(1):1 -23.
Eremina V, Cui S, Gerber H, et al [2006] Vascular endothelial growth factor a signaling in the 
podocy te-endothelial compartment is required for mesangial cell migration and survival. J Am 
Soc Nephrol; 17(3):724 -35.
Eremina V, Jefferson JA, Kowalewska J, et al [2008] VEGF inhibition and renal thrombotic 
microangiopath y. N Engl J Med; 358(11):1129-36.
European Medicines Agency  (EMEA) [2006] Avastin: EPAR -scientific discussion. 
24Jan2006. Available from:
http://www.ema.europa.eu/d ocs/en_GB/document_library /EPAR 
_Scientific_Discussion/human/000582/WC500029262.pdf (Accessed 17 Sep 2014)
European Medicines Agency  (EMEA) [2013] Eylea: EPAR - public assessment report. 
21Feb2013. Available from:
http://www.ema.europa.eu/d ocs/en_GB/document _library /EPAR 
_Public_assessment_report/human/002392/WC500135744.pdf (Accessed 17 Sep 2014)
Geloneck MM, Chuang AZ, Clark WL, et al [2014] Refractive outcomes following 
bevacizumab monotherapy  compared with conventional laser treatment: a randomized clinic al 
trial. JAMA Ophthalmol; Published online August 07, 2014 
(doi:10.1001/jamaophthalmol.2014.2772)
Gerber HP, Hillan KJ, Ryan AM, et al [1999] VEGF is required for growth and survival in 
neonatal mice. Development; 126(6):1149-59.
Gilbert C [2008] Retinopa thy of prematurity : a global perspective of the epi[INVESTIGATOR_7509], population 
of babies at risk and implications for control. Early  Hum Dev; 84(2):77-82.
Glade Bender J L, Adamson PC, Reid JM, et al [2008] Phase I trial and pharmacokinetic study 
of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology  Group 
Study . J Clin Oncol; 26(3):399
-405.
Good WV, Early Treatment for Retinopathy  of Prematurit y Cooperative Group [2004] Final 
results of the Early  Treatment for Retinopathy  of Prematu rity (ETROP) randomized trial. Trans 
Am Ophthalmol Soc; 102:233 -48.

[COMPANY_001] Confidential Page 62
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Hard y RJ, Good WV, Dobson V, et al [2004] Multicenter trial of early treatment for retinopath y 
of prematurit y: study  design. Control Clin Trials; 25(3):311 -25.
Hartnett ME, Penn JS [2012] Mechanisms and management of retinopathy  of prematurit y. 
NEngl J Med; 367(26):2515 -26.
Hoerster R, Muether P, Dahlke C, et al [2013] Serum concentrations of vascular endothelial 
growth factor in an infant treated with ranibizumab for retinopathy  of premat urity. Acta 
Ophthalmol; 91(1):e74 -5.
Honda S, Hirabay ashi H, Tsukahara Y, et al [2008] Acute contraction of the proliferative 
membrane after an intravitreal injection of bevacizumab for advanced retinopath y of 
prematurit y. Graefes Arch Clin Exp Ophthalmol; 246(7):1061-3.
Houston SK, Wykoff CC, Berrocal AM, et al [2013] Laser treatment for retinopathy  of 
prematurit y. Lasers Med Sci; 28(2):683 -92.
Hu J, Blair MP, Shapi[INVESTIGATOR_314891], et al [2012] Reactivation of retinopath y of prematurit y after 
bevacizumab injection. Arch Ophthalmol; 130(8):1000-6.
International Committee for the Classification of Retinopathy  of Prematurity  [2005] The 
international classification of retinopathy  of prematurit y revisited. Arch Ophthalmol; 
123(7):991-9.
Jang SY, Choi KS, Lee SJ [2010] Delayed -onset retinal detachment after an intravitreal 
injection of ranibizumab for zone 1 plus retinopathy  of prematurit y. J AAPOS; 14(5):457-9.
Jin K, Zhu Y, Sun Y, et al [2002] Vascular endothelial growth factor (VEGF) stimulates 
neurogenesis in vitro and in vivo. Proc Natl Acad Sci [LOCATION_003]; 99(18):[ZIP_CODE]-50.
Kiely  PM, Gillard- Crewther S, Nathan J, et al [1987] A comparison of ocular development of 
the Cy nomolgus monkey and man. Clin Vision Sci; 1(3):269-80.
Kitamoto Y, Tokunaga H, Tomita K [1997] Vascular endothelial growth factor is an essential 
molecule for mouse kidney  development: glomerulogenesis and nephrogenesis. J Clin Invest; 
99(10):2351-7.
Kvarnström G, Jakobsson P [2005] Is vision screening in 3-year-old children feasible ? 
Comparison between Lea Symbol chart and the HVOT (LM) chart Acta Ophthalmol. Scand. 
83; 76 -
80
Law JC, Recchia FM, Morrison DG, et al [2010] Intravitreal bevacizumab as adjunctive 
treatment for retinopath y of prematurit y. J AAPOS; 14(1):6-10.
Lee JY, Chae JB, Yang SJ, et al [2010] Effects of intravitreal bevacizumab and laser in 
retinopathy  of prematurity  therap y on the development of peripheral retinal vessels. Graefes 
Arch Clin Exp Ophthalmol; 248(9):1257-62.
Lee SJ, Kim SY, Yoo BC, et al[2011] Plasma level of vascular endothelial growth factor in 
retinopathy  of prematurity  after intravitreal injection of bevacizumab (E-abstract). Invest 
Ophthalmol Vis Sci; 52:3165A. Available from:
https://iovs.arvojournals.org/article.aspx?articleid=236 0939

[COMPANY_001] Confidential Page 63
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Malik AK, Beldwin ME, Peale F, et al [2006] Redundant roles of VEGF -B and PlGF during 
selective VEGF -A blockade in mice. Blood; 107(2):550- 7.Micieli JA, Surkont M, Smith AF 
[2009] A systematic analy sis of the off-label use of bevacizumab for severe retinopathy  of 
prematurit y. Am J Ophthalmol; 148(4):536 -43.
Micieli JA, Surkont M, Smith AF [2009] A Systematic Anal ysis of the Off-Label Use of 
Bevacizumab for Severe Retinopathy  of Prematurity . Am J Ophthalmol;148:536 –543
Mintz -Hittner HA, Kennedy KA, Chuang AZ, et al [2011] Efficacy  of intravitreal bevacizumab 
for stage 3+ retinopath y of prematurit y. N Engl J Med; 364(7):603 -15.
Ng EY, Connolly  BP, McNamara JA, et al [2002] A comparison of laser photocoagulation with 
cryotherap y for threshold retinopathy  of prematurity  at 10 years: Part 1. Visual function and 
structural outcome. Ophthalmology ; 109(5):928 -34.
Qiao -Grider Y, Hung LF, Kee CS, et al [2007] Normal ocular development in young rhesus 
monkey s (Macaca mulatta). Vision Res; 47(11):1424 -44.
Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists, British 
Association of Perinatal Medicine, BLISS [2008] Guideline for the Screening and Treatment 
of Retinopathy  of Prematurity . [LOCATION_006] Retinopath y of Prematurity Guideline. May 2008.
Ryan AM, Eppler DB, Hagler KE, et al [1999] Preclinical safet y evaluation of rhuMAb VEGF, 
an antiangiogenic humanized monoclonal antibody. Toxicol Pathol; 27(1):78 -86.
Şahin A, Şahin M, Cingü AK, et al [2013] Intravitreal bevacizumab monotherap y for 
retinopat hy of prematurity . Pediatr Int; 55(5):599-603.
Sato T, Kusaka S, Shimojo H, et al [2009] Vitreous levels of erythropoietin and vascular 
endothelial growth factor in eyes with retinopathy  of prematurity . Ophthalmology ; 
116(9):1599-603.
Sato T, Wada K, Arahori H, et al [2012] Serum concentrations of bevacizumab (Avastin) and 
vascular endothelial growth factor in infants with retinopathy  of prematurity . Am J Ophthalmol; 
153(2):327-33.
Smith AR, Hennessy  JM, Kurth MA, et al [2008] Reversible skeletal changes after treatment 
with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocy topenia 
syndrome. Pediatr Blood Cancer; 51(3):418-20.
Smith LE [2008] Through the eyes of a child: understanding retinopathy  through ROP the 
Friedenwald lecture. Inve st Ophthalmol Vis Sci; 49(12):5177 -82.
Sonmez K, Drenser KA, Capone A Jr, et al [2008] Vitreous levels of stromal cell-derived factor 
1 and vascular endothelial growth factor in patients with retinopathy of prematurit y. 
Ophthalmology ; 115(6):1065 -70.
Wu WC, Kuo HK, Yeh PT, et al [2013] An updated study  of the use of bevacizumab in the 
treatment of patients with prethreshold retinopath y of prematurity  in Taiwan. Am J Ophthalmol; 
155(1):150-8.

[COMPANY_001] Confidential Page 64
Amended Pro tocol Version v02 (Clean ) Protocol No. CRFB002H2301E1
Wu WC, Yeh PT, Chen SN, et al [2011] Effects and complications of bevacizumab use in 
patients with retinopathy of prematurity : a multicenter study  in Taiwan. Ophthalmology ; 
118(1):176-83.
Zepeda -Romero LC, L iera-Garcia JA, Gutierrez -Padilla JA, et al [2010] Paradoxical vascular ‑
fibrotic reaction after intravitreal bevacizumab for retinopath y of prematurity . Eye (Lond); 
24(5):931-3.
Zhou Y, Jiang Y, Bai Y, et al [2015] Vascular endothelial growth factor plasma levels before 
and after treatment of retinopathy  of prematurit y with ranibizumab. Graefes Arch Clin Exp 
Ophthalmol (DOI 10.1007/s00417-015-2996-0)
